Skip to main content

Table 4 Overall survival, quality-adjusted life years and costs per patient, base case analysis

From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain

  Undiscounted Discounted
Palivizumab No prophylaxis Difference Palivizumab No prophylaxis Difference
Life years 66.51 66.34 0.17 27.15 27.08 0.07
Quality-adjusted life years by RSV history 61.89 61.68 0.21 25.73 25.62 0.11
 No RSV 57.61 51.06 6.56 23.96 21.24 2.73
 MA-RSV 1.20 5.00 −3.80 0.49 2.07 −1.57
 RSV-H 3.08 5.63 −2.55 1.27 2.31 −1.05
Quality-adjusted life years by sequelae history
 No Sequelae 61.28 60.25 1.03 25.25 24.51 0.74
 Asthma 0.16 0.34 −0.18 0.13 0.27 −0.14
 Allergic sensitization 0.33 0.84 −0.51 0.26 0.66 −0.40
 Asthma and allergic sensitization 0.12 0.24 −0.12 0.09 0.19 −0.10
Costs € 4731 € 3220 € 1511 € 4574 € 2881 € 1693
 Prophylaxis costs € 3100 € 0 € 3100 € 3100 € 0 € 3100
 MA-RSV: Medical care € 2 € 9 -€ 7 € 80 € 334 -€ 254
 MA-RSV: Sequelae € 100 € 418 -€ 318 € 2 € 9 -€ 7
 RSV-H: Medical care € 1063 € 1941 -€ 879 € 1042 € 1904 -€ 862
 RSV-H: Sequelae € 440 € 803 -€ 364 € 326 € 595 -€ 269
 RSV-H: Nosocomial € 27 € 49 -€ 22 € 27 € 49 -€ 22
  1. Abbreviations: RSV, respiratory syncytial virus; MA-RSV, medically attended RSV infection; RSV-H, RSV infection resulting in hospitalization